Next Article in Journal
Electrochemotherapy Causes Caspase-Independent Necrotic-Like Death in Pancreatic Cancer Cells
Next Article in Special Issue
Targeting Oncogenic BRAF: Past, Present, and Future
Previous Article in Journal
Multi-Drug/Gene NASH Therapy Delivery and Selective Hyperspectral NIR Imaging Using Chirality-Sorted Single-Walled Carbon Nanotubes
Previous Article in Special Issue
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
Review

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma

by 1,2 and 3,4,5,6,*
1
Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden
2
Karolinska University Hospital Solna, 171 76 Stockholm, Sweden
3
School of Pharmacy and Biomedical Sciences, Curtin University, Perth 6845, Australia
4
Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Bentley, WA 6102, Australia
5
Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore
6
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(8), 1176; https://doi.org/10.3390/cancers11081176
Received: 2 July 2019 / Revised: 8 August 2019 / Accepted: 9 August 2019 / Published: 14 August 2019
(This article belongs to the Special Issue Oncogenic Forms of BRAF as Cancer Driver Genes)
The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma patients with BRAF (V600E) mutations has demonstrated significant clinical benefits. However, rarely do tumours regress completely. Frequently, the reason for this is that therapies targeting specific oncogenic mutations induce a number of intrinsic compensatory mechanisms, also known as adaptive responses or feedback loops, that enhance the pro-survival and pro-proliferative capacity of a proportion of the original tumour population, thereby resulting in tumour progression. In this review we will summarize the known adaptive responses that limit BRAF mutant therapy and discuss potential novel combinatorial therapies to overcome resistance. View Full-Text
Keywords: BRAF; melanoma; adaptive responses; resistance BRAF; melanoma; adaptive responses; resistance
Show Figures

Figure 1

MDPI and ACS Style

Saei, A.; Eichhorn, P.J.A. Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma. Cancers 2019, 11, 1176. https://doi.org/10.3390/cancers11081176

AMA Style

Saei A, Eichhorn PJA. Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma. Cancers. 2019; 11(8):1176. https://doi.org/10.3390/cancers11081176

Chicago/Turabian Style

Saei, Azad, and Pieter J.A. Eichhorn. 2019. "Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma" Cancers 11, no. 8: 1176. https://doi.org/10.3390/cancers11081176

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop